NLSP Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NLS Pharmaceutics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.90 |
| 52 Week High | US$20.80 |
| 52 Week Low | US$1.73 |
| Beta | -0.40 |
| 1 Month Change | -2.56% |
| 3 Month Change | -58.74% |
| 1 Year Change | -89.89% |
| 3 Year Change | -94.60% |
| 5 Year Change | n/a |
| Change since IPO | -98.36% |
Recent News & Updates
Recent updates
NLS Pharmaceutics gets delisting determination letter from Nasdaq
Oct 05NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate
Sep 27NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders
Jul 28Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation
Mar 04
Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky
Nov 12Shareholder Returns
| NLSP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.4% | -3.5% | 3.1% |
| 1Y | -89.9% | 0.2% | 23.7% |
Return vs Industry: NLSP underperformed the US Pharmaceuticals industry which returned 0.2% over the past year.
Return vs Market: NLSP underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| NLSP volatility | |
|---|---|
| NLSP Average Weekly Movement | 22.2% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NLSP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NLSP's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Alex Zwyer | nlspharma.com |
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD.
NLS Pharmaceutics AG Fundamentals Summary
| NLSP fundamental statistics | |
|---|---|
| Market cap | US$3.10m |
| Earnings (TTM) | -US$6.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs NLSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NLSP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.60m |
| Earnings | -US$6.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -18.5% |
How did NLSP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 02:15 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NLS Pharmaceutics AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| I-Eh Jen | Laidlaw & Company (UK) Ltd |